Drug Profile
Fostemsavir - ViiV Healthcare
Alternative Names: BMS 626529 prodrug; BMS-663068; BMS-663068-03; Fostemsavir extended-release; Fostemsavir trometamol; Fostemsavir tromethamine; GSK 3684934; GSK-3684934A; HIV attachment inhibitor - ViiV Healthcare; Rukobia; Temsavir prodrugLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb
- Developer Bristol-Myers Squibb; ViiV Healthcare
- Class 2 ring heterocyclic compounds; Antiretrovirals; Phosphoric acid esters; Piperazines; Pyridines; Pyrroles; Small molecules; Triazoles
- Mechanism of Action Virus attachment inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed HIV-1 infections
Most Recent Events
- 29 Jul 2022 Updated efficacy data and adverse events data from a phase III BRIGHTE trial in HIV-1 infections released by ViiV Healthcare
- 02 Feb 2022 Launched for HIV-1 infections (Treatment-experienced) in USA, United Kingdom (PO)
- 11 Aug 2021 Phase-I/II clinical trials in HIV-1 infections (Combination therapy, In adults, In adolescents, Treatment-experienced) in Spain (PO) in August 2021 (EudraCT2020-001029-30)